The reported net income is entirely non-operational (stock comp reversal). The key catalysts are the FDA interactions for Alzheimer's and Rett syndrome, and the Fragile X IND submission in September. Monitor for news on these regulatory milestones and the filing of the overdue 10-Qs, which is a prerequisite for regaining Nasdaq compliance.
Price Chart
Executive Summary
Anavex reported a net income of $7.8M ($0.08/share) for its fiscal Q3 2026, compared to a net loss of $13.2M ($-0.16/share) in the year-ago quarter. The swing to profitability was driven by a $17.4M reversal of stock-based compensation expense from the termination of the former CEO, not by operational improvement. Revenue remains zero as the company is pre-commercial, and the core pipeline narrative (FDA engagement for Alzheimer's, Rett, and Fragile X) is unchanged from the prior quarter.
Key Financial Metrics
Key Facts
- Net income of $7.8M for Q3 2026 vs. net loss of $13.2M in Q3 2025, driven by a $17.4M reversal of stock-based compensation from executive terminations.
- Cash and cash equivalents were $118.3M as of June 30, 2026, down from $127.4M at March 31, 2026, but up from $102.6M at fiscal year-end September 30, 2025.
- Company submitted all Alzheimer's clinical trial data to its IND and a formal meeting request to the FDA for Rett syndrome; Fragile X IND submission planned for September.
- Company remains out of compliance with Nasdaq listing rules and plans to file overdue 10-Qs for Q2 and Q3 2026 in the near term.
Financial Impact
Net income of $7.8M in Q3 2026 vs net loss of $13.2M in Q3 2025; cash burn of ~$9.1M from Q2 to Q3 2026.
Risk Factors
- Nasdaq delisting risk if overdue 10-Qs are not filed and compliance is not regained.
- Regulatory risk: FDA may not align with the company's proposed Phase 3 design for Alzheimer's or Rett syndrome.
- Cash burn rate: $118.3M cash runway into mid-to-late fiscal 2028 assumes no change in spending; any delays or additional studies could accelerate burn.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-001143 |
| Document: 0001731122-26-001143-index.html | 0001731122-26-001143 |
| Document: 0001731122-26-001143.txt | 0001731122-26-001143 |
| 8-K Data (Synthetic) | 0001731122-26-001143 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $1.36 | awaiting T+60 | — | $1.28 (−5.88%) |
Oct 20, 2026 6d ago | Press Release | $1.36 | awaiting T+60 | — | $1.28 (−5.88%) |
Oct 15, 2026 11d ago | 8-K | $1.31 | awaiting T+60 | — | $1.28 (−2.29%) |
Oct 15, 2026 11d ago | Press Release | $1.31 | awaiting T+60 | — | $1.28 (−2.29%) |
Sep 28, 2026 28d ago | 8-K | $2.36 | awaiting T+60 | — | $1.28 (−45.76%) |
Sep 17, 2026 5w ago | DFAN14A | $2.41 | awaiting T+60 | — | $1.28 (−46.89%) |
Sep 15, 2026 5w ago | DFAN14A | $2.44 | awaiting T+60 | — | $1.28 (−47.54%) |
Sep 14, 2026 6w ago | DEFA14A | $2.60 | awaiting T+60 | — | $1.28 (−50.77%) |
Sep 4, 2026 7w ago | DEFA14A | $2.85 | awaiting T+60 | — | $1.28 (−55.09%) |
Sep 3, 2026 7w ago | DFAN14A | $2.86 | awaiting T+60 | — | $1.28 (−55.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers